» Articles » PMID: 38472475

MSUT2 Regulates Tau Spreading Via Adenosinergic Signaling Mediated ASAP1 Pathway in Neurons

Abstract

Inclusions comprised of microtubule-associated protein tau (tau) are implicated in a group of neurodegenerative diseases, collectively known as tauopathies, that include Alzheimer's disease (AD). The spreading of misfolded tau "seeds" along neuronal networks is thought to play a crucial role in the progression of tau pathology. Consequently, restricting the release or uptake of tau seeds may inhibit the spread of tau pathology and potentially halt the advancement of the disease. Previous studies have demonstrated that the Mammalian Suppressor of Tauopathy 2 (MSUT2), an RNA binding protein, modulates tau pathogenesis in a transgenic mouse model. In this study, we investigated the impact of MSUT2 on tau pathogenesis using tau seeding models. Our findings indicate that the loss of MSUT2 mitigates human tau seed-induced pathology in neuron cultures and mouse models. In addition, MSUT2 regulates many gene transcripts, including the Adenosine Receptor 1 (A1AR), and we show that down regulation or inhibition of A1AR modulates the activity of the "ArfGAP with SH3 Domain, Ankyrin Repeat, and PH Domain 1 protein" (ASAP1), thereby influencing the internalization of pathogenic tau seeds into neurons resulting in reduction of tau pathology.

Citing Articles

Targeting Endogenous Tau in Seeded Tauopathy Models Inhibits Tau Spread.

Jang E, Hoxha K, Mozier D, Insana A, Farber E, Changolkar L J Neurosci. 2024; 44(48).

PMID: 39500576 PMC: 11604146. DOI: 10.1523/JNEUROSCI.0877-24.2024.


Unlocking the adenosine receptor mechanism of the tumour immune microenvironment.

Han Y, Dong C, Hu M, Wang X, Wang G Front Immunol. 2024; 15:1434118.

PMID: 38994361 PMC: 11236561. DOI: 10.3389/fimmu.2024.1434118.

References
1.
Piras A, Collin L, Gruninger F, Graff C, Ronnback A . Autophagic and lysosomal defects in human tauopathies: analysis of post-mortem brain from patients with familial Alzheimer disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol Commun. 2016; 4:22. PMC: 4774096. DOI: 10.1186/s40478-016-0292-9. View

2.
Lopes L, Sebastiao A, Ribeiro J . Adenosine and related drugs in brain diseases: present and future in clinical trials. Curr Top Med Chem. 2011; 11(8):1087-101. DOI: 10.2174/156802611795347591. View

3.
Cooper J, Lathuiliere A, Migliorini M, Arai A, Wani M, Dujardin S . Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism. J Biol Chem. 2021; 296:100715. PMC: 8164048. DOI: 10.1016/j.jbc.2021.100715. View

4.
Karpowicz Jr R, Haney C, Mihaila T, Sandler R, Petersson E, Lee V . Selective imaging of internalized proteopathic α-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies. J Biol Chem. 2017; 292(32):13482-13497. PMC: 5555207. DOI: 10.1074/jbc.M117.780296. View

5.
De Cecco E, Celauro L, Vanni S, Grandolfo M, Bistaffa E, Moda F . The uptake of tau amyloid fibrils is facilitated by the cellular prion protein and hampers prion propagation in cultured cells. J Neurochem. 2020; 155(5):577-591. DOI: 10.1111/jnc.15040. View